Print this page

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases.

RAPIVAB now FDA approved.

Learn More

To learn more about BioCryst Pharmaceuticals please read the company’s 2013 10K annual report.

Read our annual report

Read our Corporate Factsheet

BioCryst's core development programs include BCX4161 and two 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.

Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.